BACKGROUND: Obesity may lead to the development of multiple chronic disease states, including hypertension, dyslipidemia, and type 2 diabetes mellitus. Over a half billion adults worldwide are affected by obesity, and more than two-thirds of adults are either obese or overweight in the United States. Diet and exercise have been the mainstays of treatment in this population; however, once failed, noninvasive, long-term effective treatment modality is lacking, and medications may potentially fill the void. Lorcaserin and phentermine/topiramate were approved by the FDA in June 2012 and July 2012, respectively, as adjuncts to diet and exercise for chronic weight management of obese (body mass index [BMI] ≥ 30 kg/m 2 ) or overweight (BMI ≥ 27 kg/m 2 ) individuals with comorbidities.
What is already known about this subject
• A comprehensive summary of weight loss guidelines is provided, including those from the National Heart, Lung and Blood Institute, U.S. Preventive Services Task Force, American Diabetes Association, and American Heart Association, that emphasize treatment with lifestyle therapy but include some medication recommendations.
• Managed care considerations for coverage of weight loss agents include potential increases in drug utilization; comparative safety and efficacy of therapeutic agents; appropriate utilization management controls; and drug, medical, and overall health care costs.
• Express Scripts and Aetna's coverage of phentermine/topiramate signifies that drugs being used to treat weight loss are being considered similar to those for chronic medical conditions and not lifestyle therapy, setting the stage for smaller pharmacy benefit managers and health plans to potentially follow suit.
What this study adds
O besity is an epidemic that affects over a half billion adults worldwide and contributes to the development of multiple chronic disease states, including hypertension, dyslipidemia, and type 2 diabetes mellitus (T2DM). . 2 Diet modification and exercise have been the mainstays of treatment; however, once failed, few alternatives are available for long-term treatment, such as bariatric surgery and drug therapy. 3 Pharmacotherapy is indicated for individuals with a BMI ≥ 30 kg/m 2 , or those with a BMI ≥27 kg/m 2 and diagnosed with comorbidities such as hypertension, dyslipidemia, or T2DM. 3 Prior to June 2012, the U.S. Food and Drug Administration (FDA) approved drug therapies for obesity in the United States included phentermine, orlistat, benzphetamine, phendimetrazine, methylphenidate, and diethylpropion (Table 1) . Off-label drug therapies for obesity include other medications such as topiramate and zonisamide, an antiepileptic and antipsychotic, respectively. 3, 4 Other pharmacotherapy utilized in the past includes multiple drugs that have been discontinued and removed from the market, such as fenfluramine, dexfenfluramine, sibutramine, and mazindol (Table 2) . 3 The drug combination of phentermine and either fenfluramine or 43 benzphetamine, 44 diethylproprion, 45 methylphenidate, 46 orlistat, 47, 48 phendimetrazine, 49 phentermine, 50 
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dexfenfluramine was commonly referred to as Fen-Phen. 5 Fenfluramine, dexfenfluramine, and sibutramine were removed from the market due to cardiovascular damage concerns. 3, 6 According to the Orange Book, mazindol was not discontinued due to safety or efficacy reasons. 7 Rimonabant, which was the first selective CB1 receptor blocker, was available in 56 countries including the European Union from 2006 to 2008. However, rimonabant was never FDA-approved due to increased risk of psychiatric adverse events. Many of these agents have demonstrated short-term weight loss of a few weeks, with patients having difficulty maintaining weight loss once treatment was discontinued. 3 Hence, an opportunity exists in the marketplace for weight loss agents with long-term success rates and favorable safety profiles.
In the United States, obesity accounts for an additional $190 billion of medical spend per year, which is equivalent to 20.6% of U.S. health care expenditures. 8 Obesity rates are predicted to increase 42% by 2030, translating to an increase of $550 billion total health care spend in the United States between 2012 and 2030. Therefore, keeping obesity rates steady may potentially have a favorable economic impact on the health care industry. 9 Lifestyle changes related to diet and exercise are effective in treating many obese and overweight individuals. The Centers for Disease Control and Prevention and American Heart Association (AHA) emphasize the importance of diet and exercise by explaining the significance of reducing calorie intake and increasing calorie expenditure. However, this approach does not work for the entire population. 10, 11 A systematic review found that exercise only had a modest effect on chronic disease risk factors, such as hypertension where subjects reduced their blood pressure 4.9-6.9 millimeters of mercury (mm Hg), in obese individuals. However, investigators still recommend obese individuals to undertake physical activity within their capabilities. 12 The limited effectiveness of diet and exercise interventions in weight management suggest other treatment modalities, such as add-on pharmacotherapy, may be required for some patients. 4, 13, 14 Although lifestyle changes are the mainstay of weight management, guidelines do acknowledge pharmacotherapy in treating obese or overweight patients. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (2000), put forth by the National Heart, Lung, and Blood Institute (NHLBI), recommends that drug therapy may be useful for patients with a BMI ≥ 30 kg/m 2 with no concomitant risk factors or BMI ≥ 27 kg/m 2 with concomitant risk factors. NHLBI recommends that weight loss medications should only be used in conjunction with physical activity, diet, and behavioral therapy. Drug therapy is considered second line (ahead of weight loss surgery) and should be considered if a patient has not lost 1 pound per week after 6 months of lifestyle therapy. 4 For management of overweight and obese patients, the Adult Treatment Panel (ATP) III Cholesterol Guidelines defer to the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (1998), which recommend orlistat as an adjunct to diet and physical activity for the same target population as the 2000 NHLBI obesity guidelines. 13 In June 2012, the U.S. Preventive Services Task Force updated its recommendations, stating that clinicians should offer or refer patients 18 years or older with BMI ≥ 30 kg/m 2 to intensive, multicomponent behavioral interventions. The task force was unable to recommend medication use, despite finding that orlistat or metformin in combination with behavioral interventions resulted in weight loss and improvement of physiologic outcomes. Due to off-label use of metformin and the lack of data regarding improvements beyond medication discontinuation, the task force was unable to make a definitive recommendation. 14 The American Diabetes Association (ADA) and AHA have also established recommendations in treating obese patients. ADA recommends individualized nutrition therapy for prediabetic or diabetic patients, preferably with a registered dietician. Diabetic patients should focus on physical activity and behavioral modification, especially diet, for at least 2 years after being diagnosed. For these patients, a balanced mix of carbohydrates, fat, and protein is recommended, but the most important ) individuals with hypertension, dyslipidemia, or T2DM. Prior to June 2012, the most recent prescription obesity drug to be approved was orlistat (Xenical) in 1999. In 2007, Alli was approved, which is an over-the-counter product containing orlistat. The approval of lorcaserin and phentermine/topiramate introduces new therapeutic options in the management of obesity.
The purpose of this article is to review the clinical data of lorcaserin and phentermine/topiramate and offer insight to managed care decision makers by examining the potential impact of these medications on the U.S. health care system related to hypertension, dyslipidemia, and T2DM disease management.
■■ Methods
A MEDLINE review was performed for articles published and available through September 17, 2012, using keywords "lorcaserin" and "phentermine and topiramate" with an emphasis on published randomized controlled trials (Figure 1 ). The literature search was limited to randomized controlled trials in humans published in the English language. Additional information on lorcaserin was obtained from its FDA review on the FDA website.
■■ Results
Based on the results of the Medline review, 5 pivotal phase 3 trials were identified: 3 for lorcaserin and 2 for phentermine/ topiramate. Both agents demonstrated a statistically significant higher proportion of individuals who lost ≥ 5% of body weight, as well as higher mean weight loss when compared with placebo. Safety concerns for lorcaserin include cardiac valvulopathy and increased risk of psychiatric, cognitive, and serotonergic adverse effects. Teratogenicity and increased heart rate are major safety concerns regarding phentermine/topiramate.
Pharmacokinetics
Lorcaserin. Lorcaserin is highly bioavailable with 90% of its 10 milligram (mg) twice daily recommended dose absorbed. 16, 17 The time to maximum concentration (T max ) of lorcaserin is approximately 2 hours. A high fat meal delays the T max by 1-2 hours, but maximum concentration (C max ) and area under the curve (AUC) remain unchanged. Therefore, lorcaserin can be taken with or without food. The half-life (t 1/2 ) of lorcaserin is approximately 11 hours. Lorcaserin undergoes extensive metabolism in the liver by multiple enzymatic pathways, with the 2 major metabolites, N-sulfonate-lorcaserin (M1) and N-carbamoyl glucuronide (M5), being inactive. 16 As a mild to moderate inhibitor of CYP 2D6, lorcaserin has potential drug interactions with substrates such as dextromethorphan and desipramine, which should be monitored. Lorcaserin is 75% protein-bound with major route of elimination through the urine (92.2%). 17 When studied in clinical trials, subjects with renal dysfunction did not have a significantly altered C max or AUC. Lorcaserin was studied in subjects with mild-moderate hepatic impairment and was associated with lower C max , higher AUC, and increased t 1/2 of 5-9 hours. However, no dosage adjustment is recommended for renal or hepatic dysfunction. 16, 17 Phentermine/topiramate. Phentermine/topiramate is a oncedaily extended-release capsule combining 2 separate drugs with different pharmacokinetics. Combining the 2 drugs into 1 formulation provides an immediate release of phentermine and delayed release of topiramate, which theoretically provides better appetite suppression throughout the day. Together, the combination results in a 7-hour delay of topiramate peak concentration and an overall 29% lower C max of phentermine. The plasma concentrations of phentermine/topiramate increase approximately proportional to the dose. 18 The pharmacokinetics for phentermine are approximately dose proportional from the low dose (3.75 mg/23 mg) to high dose (15 mg/92 mg). After oral administration with the maximum dose (15 mg/92 mg) C max is 49.1 nanograms per milliliter (ng/mL) with a T max of 6 hours. A high fat meal does not affect phentermine pharmacokinetics. Phentermine is 17.5% plasma-protein bound with an estimated volume of distribution (V d ) of 348 liters (L). Phentermine has 2 metabolic pathways, p-hydroxylation and N-oxidation. Cytochrome P450 3A4 enzyme primarily metabolizes phentermine, but not extensively, resulting in little impact on drug-drug interactions. Approximately 70%-80% of a dose exists as unchanged phentermine in urine when administered alone. The terminal half-life of phentermine is approximately 20 hours. 19 The pharmacokinetics for topiramate are also approximately dose proportional from the low dose (3.75mg/23mg) to high dose (15 mg/92 mg). After oral administration with the maximum dose, C max is 1,020 ng/mL and the T max equal to 9 hours. A high fat meal does not affect topiramate pharmacokinetics. Topiramate is 15%-41% plasma-protein bound. Although not extensively metabolized, topiramate has 6 metabolites via hydroxylation, hydrolysis, and glucuronidation that do not constitute more than 5% of the administered dose. About 70% of a dose exists as unchanged topiramate in urine when percentage of body weight change when using lorcaserin 10 mg daily versus placebo were statistically significant. Lack of clinical significance (patients only lost an average 4 to 8 pounds) and meeting FDA guidance efficacy benchmarks for weight management products makes the efficacy and clinical utility of these medications questionable. FDA benchmarks include the following: (a) difference in mean weight loss must be ≥ 5% than placebo and statistically significant, and (b) proportion of patients who lose ≥ 5% in active group is ≥ 35%, and approximately twice the placebo group, with the difference being statistically significant. 24 Lorcaserin did not meet the difference in mean weight loss of ≥ 5% versus placebo. Also of concern is the high drop-out rate within the studies (33%-49%). There are no head-to-head trials with other medications used for weight loss. [21] [22] [23] Both lorcaserin and phentermine/topiramate were previously rejected by the FDA due to safety concerns. Mammary and brain tumors occurred at a higher incidence in rats treated administered alone. The terminal half-life is approximately 65 hours. 19 Due to plasma levels of topiramate increasing, dose adjustment is recommended in patients with moderate or severe renal or hepatic impairment no greater than phentermine 7.5 mg/topiramate 46 mg. 18, 20 Efficacy and Safety Lorcaserin. The efficacy and safety of lorcaserin was studied in three phase 3 pivotal trials: Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management (BLOOM); 21 the BLOSSOM trial (BLOSSOM), a 1-year randomized trial of lorcaserin for weight loss in obese and overweight adults; 22 and the BLOOM-DM study (BLOOM-DM), a randomized placebocontrolled clinical trial of lorcaserin for weight loss in T2DM. 23 The study designs, samples, efficacy, and safety outcomes are shown in Table 3A 25 The original drug application for lorcaserin also showed a higher frequency of FDA-defined valvulopathy (mild or greater aortic regurgitation and/or moderate or greater mitral regurgitation) in subjects. 23 However, in vitro receptor assays demonstrated that lorcaserin is more selective with lorcaserin in carcinogenicity studies. However, when mammary tumor data were re-evaluated, fewer tumors were categorized as malignant compared with the original drug application. Regarding brain tumors, a clinical study determined that only a small proportion of lorcaserin enters the for the 5-HT2C receptor and not 5-HT2B receptor, which is the receptor associated with valvulopathy. 26 These findings diminished the initial safety concerns, therefore, supporting a favorable benefit-risk profile for lorcaserin to gain FDA approval.
Phentermine/topiramate. The efficacy and safety of phentermine/topiramate was studied in two phase 3 pivotal trials: (1) effects of low-dose, controlled-release phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER), a randomized, placebo-controlled phase 3 trial, 27 and (2) controlled-release phentermine/topiramate in severely obese adults, a randomized controlled trial (EQUIP). 28 The study designs, samples, efficacy, and safety outcomes are shown in Table 4A and 4B.
Phentermine/topiramate was approved with statistically significant results that met FDA weight guidance efficacy benchmarks. The clinical significance of phentermine/topiramate is questionable with approximately an 8-to 21-pound average weight loss in the 2 clinical trials. Additionally, high drop-out rates were seen with phentermine/topiramate (up to 46%). [27] [28] Teratogenicity (orofacial cleft) and elevations in resting heart rate are safety concerns for phentermine/topiramate. Consequently, a risk evaluation and mitigation strategy (REMS) was required for phentermine/topiramate's approval to address teratogenicity. The REMS program includes a medication guide, patient brochure, and formal training program for prescribers. In October 2012, Vivus submitted a REMS amendment, which was approved in April 2013 by the FDA, permitting expansion to retail pharmacies-previously it was available only through specially certified mail order pharmacies. 26, 29, 30 Although phentermine/topiramate was associated with increased heart rates, the FDA decided that the greater reductions in blood pressure and weight loss supported a favorable benefit-risk balance to gain approval. 26 
■■ Discussion Managed Care Considerations
The FDA has not approved a prescription obesity drug since 1999. However, 13 years later (2012) lorcaserin and phentermine/topiramate were approved within weeks of each other. A third agent, combination naltrexone/bupropion, is anticipated to gain FDA approval in 2014. 31 Despite considerable delays between obesity drug approvals by the FDA, these drugs may soon undergo a "special medical use" approval process that will allow for accelerated clinical trials and smaller groups of patients than traditionally required by the FDA. 32 The "special medical use" approval process aligns with the U.S. government's plan to double the amount of new prescription drugs launched on the market for narrow and high-risk populations, including the morbidly obese. 33 The surge of prescription obesity drugs may have a significant impact on managed care organizations. During its first week on the market, phentermine/topiramate was covered by health plans approximately a third of the time for their members, which was higher than anticipated. 34 However, since then sales have been much lower than expected but are likely to increase with the expansion of distribution to retail pharmacies in 2013. 29 Traditionally, weight loss agents are excluded from coverage, since they are considered lifestyle drugs. However, Express Scripts, the largest pharmacy benefit management company (PBM) in the United States, has included phentermine/topiramate on its national formulary. 35 Aetna, the nation's third-largest health insurer, considers lorcaserin and phentermine/topiramate "medically necessary" when meeting certain clinical criteria. 36 Express Scripts and Aetna's coverage of these medications signifies how weight loss is being considered a chronic medical condition and not simply lifestyle therapy, setting the stage for smaller PBMs and health plans to potentially follow suit. 37 Both agents have been studied versus placebo in obese and overweight patients with comorbidities such as hypertension, dyslipidemia, or T2DM. Average weight loss at 1 year from baseline ranged from 3%-3.7% for patients taking lorcaserin, while those taking phentermine/topiramate on average lost a range of 6.7% (lowest dose) to 8.9% (recommended dose). 38 The efficacy and safety of lorcaserin and phentermine/topiramate in diabetic patients were evaluated in clinical trials. 23, 25 Statistically significant improvements in blood pressure, cholesterol, and triglycerides were observed among diabetic patients taking phentermine/topiramate but not lorcaserin. However, in the BLOSSOM trial, more patients assigned to the lorcaserin twice daily group versus placebo decreased total daily use of medications to treat hypertension (4.0% vs. 3.1%, respectively) and dyslipidemia (2.6% vs. 1.4%, respectively). 22 In the CONQUER trial, more patients had their antihypertensive drugs withdrawn in the phentermine/topiramate groups at doses of 7.5 mg/46 mg (11%) and 15 mg/92 mg (15%) than placebo (5%). 25 These data show potential for these new medications to positively impact comorbidities. The BLOOM-DM trial evaluating lorcaserin included diabetic patients taking metformin or a sulfonylurea only, while CONQUER only allowed for metformin use in evaluating phentermine/topiramate. Therefore, the efficacy and safety of lorcaserin or phentermine/ topiramate in conjunction with other antidiabetic medications is unknown. 23, 25 Drug Cost Approximately 42% of the population is projected to be obese by 2030, leading to a $549.5 billion increase in medical expenditures attributed to treatment of weight-related conditions such as T2DM, heart disease, stroke, sleep apnea, and cancer (endometrial, breast, colon).
1, 39 Furthermore, analysts project weight loss medications to produce $3.1 billion in worldwide sales by 2016. 40 Phentermine/topiramate's monthly cost of maintenance dosing ranges from $162.60 to $220.80 based on average wholesale price (AWP). Lorcaserin monthly therapy is $239.40 based on AWP. 41 With the introduction of new weight loss medications and weight loss being considered less as lifestyle therapy by managed care payers, spend in this therapeutic category traditionally excluded by health insurers will likely increase.
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Utilization Management
Utilization management is essential to prevent off-label use and ensure that weight loss medications are used appropriately as part of a comprehensive treatment plan. On December 3, 2012, the 2nd U.S. Circuit Court of Appeals in New York determined that a pharmaceutical sales representative can promote "legal, off-label uses" of FDA-approved drugs as part of the freedom of speech rights under the First Amendment. 42 Such decision is a milestone that provides pharmaceutical companies leverage to promote off-label use of their products.
The utilization management (prior authorization) criteria should consider the following factors: appropriate patient selection, lifestyle modifications, safety considerations, and requirements for continuation of therapy. Lorcaserin and phentermine/topiramate should only be used in patients with a BMI ≥ 30 kg/m 2 or BMI ≥ 27 kg/m 2 with concomitant risk factors (hypertension, dyslipidemia, or T2DM). In conjunction with medication, a reduced-calorie diet (500-600 kcal reduction) and increased physical activity (moderate exercise 30 minutes each day) should be included in a patient's weight loss treatment. Additional safety concerns of lorcaserin that should be considered are psychiatric, cognitive, and serotonergic adverse effects. 26, 43 Phentermine/topiramate is associated with increased risk of metabolic acidosis, glaucoma, and psychiatric and cognitive adverse effects. 20, 26 For continuation of pharmacotherapy with lorcaserin and phentermine/topiramate, weight loss response should be evaluated by week 12.
26,44 If a patient taking lorcaserin does not lose ≥ 5% baseline body weight by week 12, further benefit is unlikely and use should be discontinued. Phentermine/topiramate should be dose escalated or discontinued if a patient has not lost ≥ 3% baseline body weight with the 7.5 mg/46 mg dose. Following dose escalation to 15 mg/92 mg after an additional 12 weeks of treatment, weight loss should be evaluated. If weight loss of 5% from baseline is not achieved, benefit is unlikely and use should be discontinued.
The involvement of care management teams in targeting overweight and obese patients should also be considered. Nurses and/or pharmacists targeting members via telephone and encouraging adherence to a weight loss program may be to consider when developing a new strategy to fight obesity and its comorbid conditions. Comparative safety and efficacy, appropriate utilization management, and drug cost are some of the important issues to consider. Despite a great need for new therapies to treat obesity, medications used for weight loss have significant side-effect profiles and contraindications that may limit therapy. An appropriate utilization management strategy should be implemented to ensure patients receive optimal pharmacotherapeutic benefits without being exposed to significant risks.
another strategy health plans can utilize in order to optimize the member's use of lorcaserin or phentermine/topiramate. This method may also improve patient safety and monitoring for side effects.
Although the majority of oral drugs may be covered under the pharmacy benefit, health insurers may consider covering lorcaserin and phentermine/topiramate under the member's medical benefit. Aetna covers lorcaserin and phentermine/ topiramate under the medical benefit for patients who "failed to lose at least one pound per week after at least 6 months on a weight loss regimen that includes a low calorie diet, increased physical activity, behavioral therapy, and who meet either of the following selection criteria": BMI ≥ 30 kg/m 2 or BMI ≥ 27 kg/m 2 with obesity-related risk factors (coronary heart disease, dyslipidemia, hypertension, obstructive sleep apnea, T2DM). 36 This comprehensive approach has both advantages and disadvantages (Table 5) . Therefore, many factors should be considered when determining coverage under the pharmacy versus medical benefit in managing safety and cost of weight loss medications as indicated in Table 5 .
Limitations
Two limitations to this review should be noted. First, only the pivotal phase 3 randomized controlled trials were included for review. Second, no guidelines outside of the United States were included for a more broad perspective. • Encourages patients to be compliant with their medication regimens.
■■ Conclusions
• The Centers for Medicare & Medicaid Services (CMS) does not assign specific J codes to drugs that will not be covered, such as weight loss drugs.
• If CMS assigns J code, oral drugs will likely have a nonclassified J code and would make monitoring of utilization difficult.
• Utilization management is less robust on the medical benefit compared with the pharmacy benefit.
• Drugs on the medical benefit are usually paid after the drugs have already been administered unlike the pharmacy benefit in which it is more customary for drugs to undergo prior authorization before patients receive the drugs.
• Member cost share can vary, with the pharmacy benefit using a basic copay structure, while the medical benefit often employs a deductible.
• Physician offices may not have as rigorous safety precautions as pharmacies in their dispensing procedures. 
